Comparative Pharmacology
Head-to-head clinical analysis: EVAMIST versus ORTHO EST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVAMIST versus ORTHO EST.
EVAMIST vs ORTHO-EST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
None Documented
None Documented
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days.
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion.
Category C
Category C
Estrogen Replacement
Estrogen Replacement